Alternative in vitro assays in nanomaterial toxicology

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 3, Issue 6, 2011, Pages 545-573

  Hartung, Thomas ^a,b   Sabbioni, Enrico ^c,d  

^a The Johns Hopkins University   (United States)

^b UNIVERSITY OF KONSTANZ   (Germany)

^c European Center for the Sustainable Impact of Nanotechnologies   (Italy)

^d UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE APPROACH; ANIMAL WELFARE; BIOKINETICS; CHEMICAL SAFETY; DRIVING FORCES; IN-VITRO ASSAYS; NANOMATERIAL; REVOLUTIONARY CHANGES; TOXIC PROPERTIES;

ANIMALS; NANOSTRUCTURED MATERIALS;

TOXICITY;

ALUMINUM OXIDE; CERIUM OXIDE; COSMETIC; ENDOTOXIN; FULLERENE DERIVATIVE; GOLD NANOPARTICLE; MULTI WALLED NANOTUBE; NANOPARTICLE; POLYSTYRENE; PYROGEN; SILICON DIOXIDE; SILVER NANOPARTICLE; SINGLE WALLED NANOTUBE; SUNSCREEN; TITANIUM DIOXIDE; ZINC OXIDE; NANOMATERIAL;

ACUTE TOXICITY; ADAPTIVE BEHAVIOR; AIR POLLUTION; ANIMAL TESTING ALTERNATIVE; ANIMAL TESTING REPLACEMENT; ARTICLE; BIOASSAY; CANCER CELL CULTURE; CELL CONTACT; CELL GROWTH; CELL TRANSPORT; CHRONICITY; COMET ASSAY; CONTAMINATION; CRYSTAL STRUCTURE; CULTURE MEDIUM; CYTOTOXICITY; DNA ADDUCT; ECOTOXICITY; ENDOCRINE DISEASE; ENDOCYTOSIS; EXPOSURE; EYE IRRITATION; FACE VALIDITY; GENOTOXICITY; HUMAN; IMMUNOTOXICITY; LIMIT OF DETECTION; LUNG TOXICITY; MICRONUCLEUS TEST; MUTAGENICITY; NANOTOXICOLOGY; NEUROTOXICITY; NONHUMAN; PARTICLE SIZE; PHOTOTOXICITY; PHYSICAL CHEMISTRY; POROSITY; PRIORITY JOURNAL; QUALITY CONTROL; REPRODUCTIVE TOXICITY; RISK ASSESSMENT; SAMPLE SIZE; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; SKIN ABSORPTION; SKIN IRRITATION; SKIN PENETRATION; SKIN SENSITIZATION; SKIN TOXICITY; SPECIES DIFFERENCE; STANDARDIZATION; STRESS; TOXICITY TESTING; TOXICOKINETICS; ANIMAL; ANIMAL WELFARE; ETHICS; IN VITRO STUDY; MEDICAL RESEARCH; METHODOLOGY; MOUSE; PROCEDURES; RAT; STANDARDS;

ANIMAL WELFARE; ANIMALS; BIOMEDICAL RESEARCH; HUMANS; IN VITRO TECHNIQUES; MICE; NANOSTRUCTURES; RATS; RESEARCH DESIGN; TOXICITY TESTS;

EID: 84859832782     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.153     Document Type: Article

References (144)

1. Fadeel B, Kagan V, Krug H, Shvedova A, Svartengren M, Tran L, Wiklund L. There's plenty of room at the forum: potential risks and safety assessments of engineered nanomaterials. Nanotoxicol 2007, 1: 73-84.
2. Oberdörster G, Stone V, Donaldson K. Toxicology of nanoparticles: a historical perspective. Nanotoxicol 2007, 1:2-25.
3. Sauer UG. Political incentives towards replacing animal testing in nanotechnology? ALTEX 2009, 26:285-294.
4. Hartung T, Leist M. Food for thought... on the evolution of toxicology and phasing out of animal testing. ALTEX 2008, 25:91-96.
5. Coecke S, Balls M, Bowe G, Davis J, Gstraunthaler G, Hartung T, Hay R, Merten O-W, Price A, Schechtman L, et al. Guidance on good cell culture practice. ATLA-Altern Lab Anim 2005, 33:261-287.
6. Hartung T. Food for thought... on evidence-based toxicology. ALTEX 2009, 26:75-82.
7. Balls M, Amcoff P, Bremer S, Casati S, Coecke S, Clothier R, Combes R, Corvi R, Curren R, Eskes C, et al. The principles of weight of evidence validation of test methods and testing strategies. The report and recommendations of ECVAM workshop 58. ATLA-Altern Lab Anim 2006, 34:603-620.
8. Hartung T. Food for thought... on validation. ALTEX 2007, 24:67-72.
9. Schiffelers M-JWA, Blaauboer BJ, Martje Fentener van Vlissingen J, Kuil J, Remie R, Thuring JWGM, Vaal MA, Hendriksen CFM. Factors stimulating or obstructing the implementation of the 3Rs in the regulatory process. ALTEX 2007, 24:273-278.
10. Bottini AA, Alepee N, De Silva O, Hartung T, Hendriksen C, Kuil J, Pazos P, Philips B, Rhein C, Schiffelers M-J, et al. of the post-validation process. The report and recommendations of ECVAM workshop 67. ATLA-Altern Lab Anim 2008, 36:353-366.
11. Russell WMS, Burch RL. The Principles of Humane Experimental Technique. London: Methuen; 1959. Available at: (Accessed July 11, 2011).
12. Hudson M. Why do the numbers of laboratory animal procedures conducted continue to rise? An analysis of the Home Office Statistics of Scientific Procedures on Living Animals: Great Britain 2005. ATLA-Altern Lab Anim 2007, 35:177-187.
13. Bottini AA, Amcoff P, Hartung T. Food for thought... on globalization of alternative methods. ALTEX 2007, 24:255-261.
14. Hartung T. Lessons learned from alternative methods and their validation for a new toxicology in the 21st century. J Toxicol Environ Health 2010, 13:277-290.
15. Leist M, Kadereit S, Schildknecht S. Food for thought... on the real success of 3R approaches. ALTEX 2008, 25:17-24.
16. Devolder T, Reid K, Rogiers V, Webb S, Wilkins D. A review of national public funding programmes in European countries. ALTEX 2008, 25:233-242.
17. European Commission. Fifth report from the Commission to the Council and the European Parliament on the Statistics on the number of animals used for experimental and other scientific purposes in the member states of the European Union COM/2007/675 final, 2007. Available at: (Accessed July 11, 2011).
18. Hartung T, Bremer S, Casati S, Coecke S, Corvi R, Fortaner S, Gribaldo L, Halder M, Roi AJ, Prieto P, et al. ECVAM's response to the changing political environment for alternatives: consequences of the European Union chemicals and cosmetics policy. ATLA-Altern Lab Anim 2003, 31:473-481.
19. Zuang V, Hartung T. Making validated alternatives available-the strategies and work of the European Centre for the Validation of Alternative Methods (ECVAM). AATEX 2005, 11:15-26.
20. OECD, Guidance Document on the Validation and International Acceptance of New or Updated Test Methods for Hazard Assessment. Environmental Health and Safety Monograph Series on Testing and Assessment, No. 34. 2005. Available at: (Accessed July 11, 2011).
21. Hoffmann S, Edler L, Gardner I, Gribaldo L, Hartung T, Klein C, Liebsch M, Sauerland S, Schechtman L, Stammati A, et al. Points of reference in validation-the report and recommendations of ECVAM workshop. ATLA-Altern Lab Anim 2008, 36:343-352.
22. Daneshian M, Leist M, Hartung T. Center for alternatives to animal testing-Europe (CAAT-EU): a transatlantic bridge for the paradigm shift in toxicology. ALTEX 2010, 27:63-69.
23. Hartung T. Food for thought... on alternative methods for cosmetics safety testing. ALTEX 2008, 25:147-162.
24. Bottini AA, Hartung T. Food for thought... on economics of animal testing. ALTEX 2009, 26:3-16.
25. European Commission. Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC. Off J Eur Union 2006, 396:1-849.
26. Hartung T. Food for thought... on alternative methods for chemical safety testing. ALTEX 2010, 27: 3-14.
27. Rovida C, Hartung T. Re-evaluation of animal numbers and costs for in vivo tests to accomplish REACH legislation requirements for chemicals. ALTEX 2009, 26:187-208.
28. Hartung T, Rovida C. Chemical regulators have overreached. Nature 2009, 460:1080-1081.
29. Gilbert N. Streamlined chemical tests rebuffed. Nature 2010, 463:142-143.
30. Dusinska M, NanoTEST consortium. Testing strategies for the safety of nanoparticles used in medical applications. Nanomed 2009, 4:605-607.
31. Greim H, Arand M, Autrup H, Bolt HM, Bridges J, Dybing E, Glomot R, Foa V, Schulte-Hermann R. Toxicological comments to the discussion about REACH. Arch Toxicol 2006, 80:121-124.
32. EPA. 2009. Available at: (Accessed July 11, 2011).
33. National Research Council. Committee on Toxicity Testing and Assessment of Environmental Agents, National Research Council: Toxicity Testing in the 21st Century: A Vision and a Strategy. Washington, DC: The National Academies Press; 2007, 196.
34. Blaauboer BJ, Andersen ME. The need for a new toxicity testing and risk analysis paradigm to implement REACH or any other large scale testing initiative. Arch Toxicol 2007, 81:385-387.
35. Gibb S. A review of the National Research Council report Toxicity testing in the 21st century: a vision and a strategy. Reprod Toxicol 2008, 25:136-138.
36. Leist M, Hartung T, Nicotera P. The dawning of a new age of toxicology. ALTEX 2008, 25:103-114.
37. Hartung T. Toxicology for the twenty-first century. Nature 2009, 460:208-212.
38. Kavlock RJ, Austin CP, Tice RR. Commentary-toxicity testing in the 21st century: implications for human health risk assessment. Risk Anal 2009, 29:485-487.
39. Andersen ME, Krewski D. Toxicity testing in the 21st century: bringing the vision to life. Toxicol Sci 2009, 107:324-330.
40. Collins FS, Gray GM, Bucher JR. Toxicology: transforming environmental health protection. Science 2008, 319:906-907.
41. Seidle T, Stephens ML. Bringing toxicology into the 21st century: a global call to action. Toxicol in Vitro 2009, 23:1576-1579.
42. Kavlock RJ. The future of toxicity testing-the NRC vision and the EPA's ToxCast program national center for computational toxicology. Neurotoxicol Teratol 2009, 31:237.
43. Hartung T. A toxicology for the 21st century: mapping the road ahead. Toxicol Sci 2009, 109:18-23.
44. Hartung T. Towards a new toxicology-evolution or revolution? ATLA-Altern Lab Anim 2008, 36: 635-639.
45. Hoffmann S, Hartung T. Towards an evidence-based toxicology. Human Exp Toxicol 2006, 25:497-513.
46. Griesinger C, Hoffmann S, Kinsner-Ovaskainen A, Coecke S, Hartung T. Proceedings of the first international forum towards evidence-based toxicology. Conference Centre Spazio Villa Erba, Como, Italy, 15-18 October 2007. Human Exp Toxicol 2009, 28:81-163, Special Issue: Evidence-Based Toxicology (EBT).
47. Hartung T. Food for thought... on cell culture. ALTEX 2007, 24:143-147.
48. Hartung T. Food for thought... on animal tests. ALTEX 2008, 25:3-9.
49. Hartung T, Daston G. Are in vitro tests suitable for regulatory use? Toxicol Sci 2009, 111:233-237.
50. Hartung T, Hoffmann S. Food for thought on... in silico methods in toxicology. ALTEX 2009, 26: 155-166.
51. Hoffmann S, Hartung T. Diagnosis: Toxic!-trying to apply approaches of clinical diagnostics and prevalence in toxicology considerations. Toxicol Sci 2005, 85:422-428.
52. Fisher HC, Chan WCW. Nanotoxicity: the growing need for in vivo study. Curr Opin Biotech 2007, 18:565-571.
53. Garnett MC, Kallinterni P. Nanomedicine and nanotoxicology: some physiological principles. Occupat Med 2006, 56:307-311.
54. Di Gioacchino M, Verna N, Gornati R, Sabbioni E, Bernadini G. Metal nanoparticle health risk assessment. In: Sahu SC, Casciano DA, eds. Nanotoxicity-From In Vitro Models to Health Risks. Chichester: John Wiley & Sons; 2009, 519-541.
55. Donaldson K, Stone V, Tran CL, Kreyling W, Borm PJA. Nanotoxicology. Occup Environ Med 2004, 61:727-728.
56. Kagan VE, Bayir H, Shvedova AA. Nanomedicine and nanotoxicology: two sides of the same coin. Nanomed Nanotech Biol Med 2005, 1:313-316.
57. Seaton A, Donaldson K. Nanoscience, nanotoxicology, and the need to think small. Lancet 2005, 365:923-924.
58. Kipen HM, Laskin DL. Smaller is not always better: nanotechnology yields nanotoxicology. Am J Physiol Lung Cell Mol Physiol 2005, 289:L696-L697.
59. Holl MMB. Nanotoxicology: a personal perspective. WIREs Nanomed Nanobiotechnol 2009, 1:353-359.
60. Gornati R, Papis E, Di Gioacchino M, Sabbioni E, Dalle Donne I, Milzani A, Bernadini G. In vivo and in vitro models for nanotoxciology testing. In: Sahu SC, Casciano DA, eds. Nanotoxicity-From In Vitro Models to Health Risks. Chichester, UK: John Wiley & Sons; 2009, 279-302.
61. Pal S, Tak YK, Song JM. Does the antibacterial activity of silver nanoparticles depend on the shape of the nanoparticle? A study of the gram-negative bacterium Escherichia coli. Appl Environ Microbiol 2007, 73:1712-1720.
62. Chen M, Goodman DW. Catalytically active gold: From nanoparticles to ultrathin films. Acc Chem Res 2006, 39:739-746.
63. Cha EK, Myung H. Cytotoxic effects of nanoparticles assessed in vitro and in vivo. J Microbiol Biotechnol 2007, 17:1573-1578.
64. Walker NJ, Bucher JR. A 21st century paradigm for evaluating the health hazards of nanoscale materials? Toxicol Sci 2009, 110:251-254.
65. Hillyer JF, Albrecht RM. Gastrointestinal persorption and tissue distribution of differently sized colloidal gold nanoparticles. J Pharma Sci 2001, 90: 1927-1936.
66. Hillegass JM, Shukla A, Lathrop SA, MacPherson MB, Fukagawa NF, Mossman BT. Assessing nanotoxicity in cells in vitro. WIREs Nanomed Nanobiotechnol 2010, 2:219-231. doi:10.1002/wnan.054.
67. Choi J-Y, Ramachandrran G, Kandlikar M. The impact of toxicity testing costs on nanomaterial regulation. Environ Sci Technol 2009, 43:3030-3034.
68. Ponten J. Cell biology of precancer. Eur J Cancer 2001, 37(Suppl. 8):97-113.
69. Frank SA, Nowak MA. Problems of somatic mutation and cancer. Bioessays 2004, 26:291-299.
70. Stacey GN, Hartung T. Availability, standardization and safety of human cells and tissues for drug screening and testing. In: Marx U, Sandig V, eds. Drug Testing In Vitro: Breakthroughs and Trends in Cell Culture Technology. Weinheim: Wiley-VCH Verlag; 2007, 231-250.
71. Markovic O, Markovic N. Cell cross-contamination in cell cultures: the silent and neglected danger. In Vitro Cell Dev Biol Anim 1998, 34:1-8.
72. MacLeod RA, Dirks WG, Matsuo Y, Kaufmann M, Milch H, Drexler HG. Widespread intraspecies cross-contamination of human tumor cell lines arising at source. Int J Cancer 1999, 83:555-563.
73. Buehring GC, Eby EA, Eby MJ. Cell line cross-contamination: how aware are Mammalian cell culturists of the problem and how to monitor it? In Vitro Cell Dev Biol Anim 2004, 40:211-215.
74. Nardone RM. Eradication of cross-contaminated cell lines: a call for action. Cell Biol Toxicol 2007, 23:367-372.
75. Kuhlmann I. Zur Problematik des prophylaktischen Antibiotikaeinsatzes in Zellkultur (Problems of the prophylactic use of antibiotics in cell culture). ALTEX 1993, 2:27-49.
76. Kuhlmann I. The prophylactic use of antibiotics in cell culture. Cytotechnology 1995, 19:95-105.
77. Coecke S, Ahr H, Blaauboer BJ, Bremer S, Casati S, Castell J, Combes R, Corvi R, Crespi CL, Cunningham ML, et al. Metabolism: a bottleneck in in vitro toxicological test development. ATLA-Altern Lab Anim 2006, 34:49-84.
78. Hartung T, Balls M, Bardouille C, Blanck O, Coecke S, Gstraunthaler G, Lewis D. Report of ECVAM task force on good cell culture practice (GCCP). ATLA-Altern Lab Animal 2002, 30:407-414.
79. Monteiro-Riviere NA, Inman AO. Challenges for assessing carbon nanomaterial toxicity to the skin. Carbon 2006, 44:1070-1078.
80. Monteiro-Riviere NA, Inman AO, Zhang LW. Limitations and relative utility of screening assays to assess engineered nanoparticle toxicity in a human cell line. Toxicol Appl Pharmacol 2009, 234:222-235.
81. Kroll A, Pillukat MH, Hahn D, Schnekenburger J. Current in vitro methods in nanoparticle risk assessment: limitations and challenges. Eur J Pharmaceut Biopharmaceut 2009, 72:370-377.
82. Stone V, Johnston H, Schins RP. Development of in vitro systems for nanotoxicology: methodological considerations. Crit Rev Toxicol 2009, 39:613-626.
83. 2 and ZnO water suspensions. Water Res 2006, 40:3527-3532.
84. Sager TM, Porter DW, Robinson VA, Lindsley WG, Schwegler-Berry DE, Castranova V. Improved method to disperse nanoparticles for in vitro and in vivo investigation of toxicity. Nanotoxicol 2007, 1:118-129.
85. Jones CF, Grainger DW. In vitro assessments of nanomaterial toxicity. Adv Drug Deliv Rev 2009, 61:438-456.
86. Woerle-Knirsch JM, Pulskamp K, Krug HF. Oops they did it again! Carbon nanotubes hoax scientists in viability assays. Nano Lett 2006, 6:1261-1268.
87. Powers KW, Palazuelos M, Moudgil BM, Roberts SM. Characterization of the size, shape, and state of dispersion of nanoparticles for toxicological studies. Nanotoxicol 2007, 1:42-51.
88. Unfried K, Albrecht C, Klotz L-O, von Mikecz A, Grether-Beck S, Schins RFF. Cellular responses to nanoparticles: target structure and mechanisms. Nanotoxicol 2007, 1:52-71.
89. Bouvier d'Yvoire M, Prieto P, Blaauboer BJ, Bois FY, Boobis A, Brochot C, Coecke S, Freidig A, Gundert-Remy U, Hartung T, et al. Physiologically-based Kinetic Modelling (PBK Modelling): meeting the 3Rs Agenda. The report and recommendations of ECVAM workshop 63. ATLA-Altern Lab Anim 2007, 35:661-671.
90. Mailander V, Landfester K. Interaction of nanoparticles with cells. Biomacromolecules 2009, 10:2379-2400.
91. Caldorera-Moore M, Guimard N, Shi L, Roy K. Designer nanoparticles: incorporating size, shape and triggered release into nanoscale drug carriers. Expert Opin Drug Deliv 2010, 7:479-495.
92. Scott L, Eskes C, Hoffman S, Adriaens E, Alepee N, Bufo M, Clothier R, Facchini D, Faller C, Guest R, et al. A proposed eye irritation testing strategy to reduce and replace in vivo studies using bottom-up and top-down approaches. Toxicol In Vitro 2010, 24:1-9.
93. Bulgheroni A, Kinsner-Ovaskainen A, Hoffmann S, Hartung T, Prieto P. Estimation of acute oral toxicity using no adverse effect level (NOAEL) from the 28-day repeated dose toxicity studies in rats. Reg Tox Pharmacol 2009, 53:16-19.
94. Kinsner-Ovaskainen A, Bulgheroni A, Hartung T, Prieto P. ECVAM's ongoing activities in the area of acute oral toxicity. Toxicol In vitro 2009, 23:1535-1540.
95. Gennari A, Berghe C, Casati S, Castell J, Clemedson C, Coecke S, Colombo A, Curren R, Negro GD, Goldberg A, et al. Strategies to replace in vivo acute systemic toxicity testing. ATLA-Altern Lab Anim 2004, 32:437-459.
96. Kirkland D, Aardema M, Henderson L, Muller L. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and noncarcinogens I. Sensitivity, specificity and relative predictivity. Mutat Res 2005, 584:1-256.
97. Kirkland D, Pfuhler S, Tweats D, Aardema M, Corvi R, Darroudi F, Elhajouji A, Glatt H, Hastwell P, Hayashi M, et al. How to reduce false positive results when undertaking in vitro genotoxicity testing and thus avoid unnecessary follow-up animal tests: report of an ECVAM workshop. Mutat Res 2007, 628:31-55.
98. Hartung T, Bremer S, Casati S, Coecke S, Corvi R, Fortaner S, Gribaldo L, Halder M, Hoffmann S, Roi AJ, et al. A modular approach to the ECVAM principles on test validity. ATLA-Altern Lab Anim 2004, 32:467-472.
99. Basketter D, Cockshott A, Corsini E, Gerberick GF, Idehara K, Kimber I, van Loveren H, Matheson J, Mehling A, Omori T, et al. An evaluation of performance standards and non-radioactive endpoints for the local lymph node assay. The report and recommendations of ECVAM workshop 65. ATLA-Altern Lab Anim 2008, 36:243-257.
100. Casati S, Aeby P, Basketter DA, Cavani A, Gennari A, Gerberick GF, Griem P, Hartung T, Kimber I, Lepoittevin J-P, et al. Dendritic cells as a tool for the predictive identification of skin sensitisation hazard. ATLA-Altern Lab Anim 2005, 33:47-62.
101. Kimber I, Agius R, Basketter D, Corsini E, Cullinan P, Dearman R, Gimenez-Arnau E, Greenwell L, Hartung T, Kuper F, et al. Chemical respiratory allergy: opportunities for hazard identification and characterisation. The report and recommendations of ECVAM workshop 60. ATLA-Altern Lab Anim 2007, 35:243-265.
102. Basketter D, Pease C, Kasting G, Kimber I, Casati S, Cronin M, Diembeck W, Gerberick F, Hadgraft J, Hartung T, et al. Skin sensitisation and epidermal disposition: the relevance of epidermal disposition for sensitisation hazard identification and risk assessment. The report and recommendations of ECVAM workshop 59. ATLA-Altern Lab Anim 2007, 35:137-154.
103. Gerberick F, Aleksic M, Basketter D, Casati S, Karlberg A-T, Kern P, Kimber I, Lepoittevin JP, Natsch A, Ovigne JM, et al. Chemical reactivity measurement and the predictive identification of skin sensitisers-the report and recommendations of ECVAM workshop 64. ATLA-Altern Lab Anim 2008, 36:215-242.
104. Hareng L, Pellizzer C, Bremer S, Schwarz M, Hartung T. The integrated project ReProTect: a novel approach in reproductive toxicity hazard assessment. Reprod Toxicol 2005, 20:441-452.
105. Prieto P, Baird AW, Blaauboer BJ, Vicente J, Ripoll C, Corvi R, Dekant W, Dietl P, Gennari A, Gribaldo L, et al. The assessment of repeated dose toxicity in vitro: a proposed approach. ATLA-Altern Lab Anim 2006, 34:315-341.
106. Jeram S, Riego Sintes JM, Halder M, Baraibar Fentanes J, Sokull-Klüttgen B, Hutchinson TH. A strategy to reduce the use of fish in acute ecotoxicity testing of new chemical substances notified in the European Union. Reg Tox Pharmacol 2005, 42:218-224.
107. Gennari A, Ban M, Braun A, Casati S, Corsini E, Dastych J, Descotes J, Hartung T, Hooghe-Peters House R, et al. The use of in vitro systems for evaluating immunotoxicity: the report and recommendations of an ECVAM workshop. J Immunotox 2005, 2:61-83.
108. Langezaal I, Hoffmann S, Hartung T, Coecke S. Evaluation and prevalidation of an immunotoxicity test based on human whole blood cytokine release. ATLA-Altern Lab Anim 2002, 30:581-595.
109. Carfi M, Gennari A, Malerba I, Corsini E, Pallardy M, Pieters M, Van Loveren H, Vohr HW, Hartung T, Gribaldo L. In vitro tests to evaluate immunotoxicity: a preliminary study. Toxicol 2007, 229:11-22.
110. Hoffmann S, Peterbauer A, Schindler S, Fennrich S, Poole S, Mistry Y, Montag-Lessing T, Spreitzer I, Loschner B, vam Aalderen M, et al. International validation of novel pyrogen tests based on the human fever reaction. J Immunol Meth 2005, 298:161-173.
111. Schindler S, Spreitzer I, Loschner B, Hoffmann S, Hennes K, Halder M, Brügger P, Frey E, Hartung T, Montag T. International validation of pyrogen tests based on cryopreserved human primary blood cells. J Immunol Meth 2006, 316:42-51.
112. Daneshian M, von Aulock S, Hartung T. Assessment of pyrogenic contaminations with the validated human whole blood assay. Nature Protocols 2009, 12:1709-1721.
113. Schindler S, von Aulock S, Daneshian M, Hartung T. Development, validation and applications of the monocyte activation test for pyrogens based on human whole blood. ALTEX 2009, 26:293-305.
114. OECD, Environment, Health and Safety Publications Series on the Safety of Manufactured Nanomaterials No. 6. Working party on manufactured nanomaterials: list of manufactured nanomaterials and list of endpoints for phase one of the OECD testing programme, 2008. Available at:
115. Sabbioni E. In vitro nanotoxicology research. A great potential for nuclear and radiochemical techniques, 8th International Conference on Nuclear Activation Techniques in the Life Sciences (NAMLS-8), Rio de Janeiro, Brazil, 17-22 April 2005. Available at:
116. des Rieux A, Fievez V, Garinot M, Schneider YJ, Preat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release 2006, 116:1-27.
117. Emerich DF, Thanos CG. Targeted nanoparticle-based drug delivery and diagnosis. J Drug Target 2007, 15:163-183.
118. Elder A, Vidyasagar S, De Louise L. Physicochemical factors that affect metal and metal oxide nanoparticle passage across epithelial barriers. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2009, 1:434-450.
119. Yang W, Peters JI, Williams RO. Inhaled nanoparticles-a current review. Int J Pharm 2008, 356:239-47.
120. Card JW, Zeldin DC, Bonner JC, Nestmann ER. Pulmonary applications and toxicity of engineered nanoparticles. Am J Physiol Lung Cell Mol Physiol 2008, 295:L400-L411.
121. Muhlfeld C, Gehr P, Rothen-Rutishauser B. Translocation and cellular entering mechanisms of nanoparticles in the respiratory tract. Swiss Med Wkly 2008, 138:387-391.
122. Dobrovolskaia MA, Aggarwal P, Hall JB, McNeil SE. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm 2008, 5:487-95.
123. Aggarwal P, Hall JB, McLeland CB, Dobrovolskaia MA, McNeil SE. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev 2009, 61:428-437.
124. Sabbioni E. Nanoparticles toxicology research at JRC and its approach, Informal meeting on Nanoparticles and Nanotechnologies hosted by Austrian Presidency, Vienna, Austria, 2006. Available at:
125. Behra R, Krug H. Nanoparticles at large. Nature Nanotech 2008, 3:253-254.
126. Lubick N. Nanosilver toxicity: ions, nanoparticles or both? Environ Sci Technol 2008, 42:8617.
127. Ponti J, Sabbioni E, Munaro B, Broggi F, Marmorato P, Franchini F, Colognato R, Rossi F. Genotoxicity and morphological transformation induced by cobalt nanoparticles and cobalt chloride: an in vitro study in Balb/3T3 mouse fibroblasts. Mutagenesis 2009, 24:439-445.
128. Broggi F. 'Quadri metabolici, genotossicita' e potenziale cancerogeno in vitro di cobalto nano particelle, Thesis, Faculty of Matemathics, Physical and Natural Sciences, University of the Insubria (Varese), Italy, Academic year 2005-2006.
129. Sabbioni E. Nanotossicologia, ricerca e metodi alternativi: la strategia europea, Simposio Italiano di Nanotossicologia, Università dell'Insubria, 28 February 2007. Available at: (Accessed June 23, 2011).
130. Papis E, Gornati R, Ponti J, Prati M, Sabbioni E, Bernardini G. Gene expression in nanotoxicology: a search for biomarkers of exposure to cobalt particles and ions. Nanotoxicol 2007, 1:198-203.
131. Linse S, Cabaleiro-Lago C, Xue WF, Lynch I, Lindman S, Thulin E, Radford SE, Dawson KA. Nucleation of protein fibrillation by nanoparticles. Proc Natl Acad Sci U S A 200:8691-8696.
132. Sabbioni E, Ponti J, Del Torchio R, Farina M, Fortaner S, Munaro B, Sasaki T, Rossi F. Recherche in vitro sur la toxicologie des nanoparticules au Joint Research Center. Méd Nucl - Imagerie fonctionnelle métabolique 2006, 30:15-23.
133. Limbach LK, Wick P, Manser P, Grass RN, Bruinink A, Stark WJ. Exposure of engineered nanoparticles to human lung epithelial cells: influence of chemical composition and catalytic activity on oxidative stress. Environ Sci Technol 2007, 41:3791-3792.
134. Colagnato R, Bonelli A, Poni J, Farina M, Bergamaschi E, Sabbioni E, Migliore L. Comparative genotoxicity of cobalt nanoparticles and ions on human peripheral leukocytes in vitro. Mutagenesis 2008, 23:377-382.
135. Sabbioni E, Gatti AM, Hartung T. Pathology of new diseases induced by nanomaterials and in vitro toxicology research, XXV Congress of the International Academy of Pathology Brisbane, 10-15 October 2004. Pathol Int 2004, 50:S141-S148.
136. Chavanpatil MD, Khdair A, Panyam J. Nanoparticles for cellular drug delivery: mechanisms and factors influencing delivery. J Nanosci Nanotechnol 2006, 6:2651-2663.
137. Harush-Frenkel O, Altschuler Y, Benita S. Nano- particle-cell interactions: drug delivery implications. Crit Rev Ther Drug Carrier Syst 2008, 25:485-544.
138. OECD, Series on principles of good laboratory practice and compliance monitoring, Number 14, Advisory Document of the Working Group on Good Laboratory Practice, The Application of the Principles of GLP to in vitro Studies, 2004. Available at:
139. Maynard AD, Aitken RJ, Butz T, Colvin V, Donaldson K, Oberdörster G, Philbert MA, Ryan J, Seaton A, Stone V, et al. Safe handling of nanotechnology. Nature 2006, 444:267-269.
140. Balbus JM, Maynard AD, Colvin VL, Castranova V, Daston GP, Denison RA, Dreher KL, Goering PL, Goldberg AM, Kulinowski KM, et al. Meeting report: hazard assessment for nanoparticles-report from an interdisciplinary workshop. Environ Health Perspect 2007, 115:1654-1659.
141. Warheit DB, Borm PJ, Lademann HCJ. Testing strategies to establish the safety of nanomaterials: conclusions of an ECETOC workshop. Inhal Toxicol 2007, 19:631-643.
142. Hoet P, Boczkowski J. What's new in nanotoxicology? Brief review of the 2007 literature. Nanotoxicol 2008, 2:171-182.
143. Elliott KC. Varieties of exploratory experimentation in nanotoxicology. Hist Phil Life Sci 2007, 29:313-336.
144. Ashwood P, Thompson RP, Powell JJ. Fine particles that adsorb lipopolysaccharide via bridging calcium cations may mimic bacterial pathogenicity towards cells. Exp Biol Med 2007, 232:107-117.